These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 3735684)

  • 1. [Clinical study of the relation between staging and survival time in patients with multiple myeloma].
    Shindo T; Nishinarita S; Shimada H; Tomura K; Sawada S; Amaki I
    Rinsho Ketsueki; 1986 Mar; 27(3):307-14. PubMed ID: 3735684
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical staging of multiple myeloma. Comparison of 7 different systems].
    Pasqualetti P; Casale R; Colantonio D
    G Clin Med; 1988 Dec; 69(12):741-50. PubMed ID: 3243405
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evaluation of the prognosis and response to therapy in multiple myeloma].
    Venturino M; Geniram A; Guarino P; Scio P; Marini U
    Recenti Prog Med; 1984 May; 75(5):451-61. PubMed ID: 6484288
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
    Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and therapeutic results in multiple myeloma.
    Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
    Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
    Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors and staging of myelomatosis].
    Bjerrum OW; Videbaek A
    Ugeskr Laeger; 1985 Apr; 147(15):1258-62. PubMed ID: 4002390
    [No Abstract]   [Full Text] [Related]  

  • 11. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of bone marrow fibrosis in multiple myeloma.
    Subramanian R; Basu D; Dutta TK
    Pathology; 2007 Oct; 39(5):512-5. PubMed ID: 17886102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of stratification systems in multiple myeloma. II. Clinical staging systems.
    Scudla V; Indrák K
    Neoplasma; 1985; 32(4):481-93. PubMed ID: 4047259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
    Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic factors in myeloma. Step-by-step regression analysis (Cox method)].
    López Pascual J; García Ahumada F; Montero J; Fernández-Rañada JM
    Rev Clin Esp; 1987 Apr; 180(7):357-63. PubMed ID: 3602548
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
    Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
    Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of 2 prognostic classification systems for myeloma and examination of the correlation between initial bone marrow plasmacytosis and prognosis. A propos of a homogeneous population of 50 patients followed from diagnosis to death].
    Pesce A; Cassuto JP; Grisot C; Gratecos N; Bayle J; Viot G; Dujardin P
    Nouv Rev Fr Hematol (1978); 1983; 25(5):311-7. PubMed ID: 6657481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
    Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
    Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.